Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Genes Chromosomes Cancer. 2010 Nov;49(11):1062-9. doi: 10.1002/gcc.20815.

Use of cancer-specific genomic rearrangements to quantify disease burden in plasma from patients with solid tumors.

Author information

  • 1Wellcome Trust Sanger Institute, Hinxton, Cambridgeshire, UK.

Abstract

Detection of recurrent somatic rearrangements routinely allows monitoring of residual disease burden in leukemias, but is not used for most solid tumors. However, next-generation sequencing now allows rapid identification of patient-specific rearrangements in solid tumors. We mapped genomic rearrangements in three cancers and showed that PCR assays for rearrangements could detect a single copy of the tumor genome in plasma without false positives. Disease status, drug responsiveness, and incipient relapse could be serially assessed. In future, this strategy could be readily established in diagnostic laboratories, with major impact on monitoring of disease status and personalizing treatment of solid tumors.

© 2010 Wiley-Liss, Inc.

PMID:
20725990
[PubMed - indexed for MEDLINE]
PMCID:
PMC3145117
Free PMC Article

Images from this publication.See all images (3)Free text

Figure 1
Figure 2
Figure 3
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for John Wiley & Sons, Inc. Icon for PubMed Central
    Loading ...
    Write to the Help Desk